CDH1 and urinary bladder carcinoma: Such a study design would provide more robust insights into the role of p53 and E-cadherin expression in bladder cancer progression and potentially inform the development of improved diagnostic and prognostic markers that could guide personalized treatment decisions and ultimately improve patient outcomes.